▎药明康德内容团队编辑
今日,美国FDA宣布授予molnupiravir紧急使用授权(EUA),用于治疗轻度到中度新冠疾病的成人患者。这也是继昨日辉瑞的Paxlovid之后,美国FDA在短短两天时间内给予授权的又一款口服抗新冠疗法。
药明康德内容团队制图
图片来源:默沙东官网
参考资料:
[1] Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults, Retrieved December 23, 2021, from https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain
[2] Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19, Retrieved December 23, 2021, from https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-receives-u-s-fda-emergency-use-authorization-for-the-treatment-of-high-risk-adults-with-mild-to-moderate-covid-19/
版权说明:本文来自药明康德内容团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”,获取转载须知。
分享,点赞,在看,聚焦全球生物医药健康创新